Tag: #ECO2026

Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds

A sub-group analysis of the ATTAIN-1 and ATTAIN-2 trials finds that orforglipron produced significant reductions in body weight and HbA1c in adults aged 65 and older, with a safety profile consistent with younger populations.

WeightControl.com Interview with:
Deborah B. Horn, DO, MPH, FOMA
Medical Director for Center of Obesity Medicine and Metabolic Performance
McGovern Medical School
UTHealth Houston, Texas

A new sub-group analysis of two major clinical trials examines how the oral GLP-1 medication orforglipron performs in adults aged 65 and older — with encouraging findings on both efficacy and safety. Continue reading “Orforglipron Shows Significant Weight Loss and Safety Benefits in Adults 65 and Older, New Analysis Finds”

Children’s Requests for Unhealthy Foods: What’s Driving Pester Power and What Can Parents Do?

A new survey of over a thousand parents finds that more than half report their children frequently request unhealthy foods while shopping — with in-store placement, packaging, and advertising among the biggest drivers.

WeightControl.com Interview with:
Professor Emma Boyland PhD MBA MSc BSc
Chair of Food Marketing and Child Health
Deputy Dean for the Institute of Population Health
University of Liverpool
UK

A new analysis presented at ECO 2026 examines how food environments drive childhood obesity through children’s requests for unhealthy products — and what parents and policymakers can do about it. Continue reading “Children’s Requests for Unhealthy Foods: What’s Driving Pester Power and What Can Parents Do?”

GLP-1 Medications and Long-Term Health Outcomes: What Real-World Data Reveals About Stopping Treatment

Real-world data shows that patients who stay on GLP-1 medications are more likely to maintain meaningful weight loss and avoid serious health complications — while those who stop treatment face greater risk.

WeightControl.com Interview with:
John Wilding DM FRCP
Professor of Medicine & Honorary Consultant Physician
Department of Cardiovascular and Metabolic Medicine
Institute of Life Course and Medical Sciences
Clinical Sciences Centre
Aintree University Hospital
Liverpool, United Kingdom

A large real-world analysis of electronic health records and health claims data in the United States examines what happens to patients prescribed GLP-1 based treatments — and what the consequences are when they stop.

Continue reading “GLP-1 Medications and Long-Term Health Outcomes: What Real-World Data Reveals About Stopping Treatment”